IJPSR (2014), Volume 5, Issue 9



INTERNATIONAL JOURNAL



Received on 12 March 2014; received in revised form, 22 April 2014; accepted, 07 June 2014; published 01 September 2014

IN-VITRO ANTIUROLITHIATIC POTENTIAL OF VARIOUS EXTRACTS OF *MUCUNA PRURIENS*

S. Vamsi^{*}, M. Raviteja and G. Siva Kumar

Department of Pharmacology, Sree Vidyanikethan College of Pharmacy, Tirupathi, Chittore - 517102, Andhra Pradesh, India.

Keywords:

Calcium oxalate crystals, Antiurolithiatic activity, Spectrophotometer, Microscope Correspondence to Author:

S. Vamsi

Department of Pharmacology, Sree Vidyanikethan College of Pharmacy, Tirupathi, Chittore - 517102, Andhra Pradesh, India.

E-mail: withyouvamsi@gmail.com

ABSTRACT: The present study was aimed to investigate the methanolic (MEMP), ethyl acetate (EEMP) and n-hexane (HEMP) extracts of the whole plant of Mucuna pruriens for their in-vitro Antiurolithiatic potential. Calcium oxalate crystallization was induced by the addition of 0.01M sodium oxalate solutions in synthetic urine. The in-vitro antiurolithiatic activity of various extracts of *M. pruriens* was investigated by measuring the turbidity of various concentrations of (50µg m/ml, 100µg m/ml, 150µg m/ml, 200µg m/ml, and 250µg m/ml) each extract in synthetic urine, by using UV/Visible spectrophotometer at 620 nm after incubating them for 10 min and microscopically under microscope equipped with digital camera at 10X. The results of the present study showed that the MEMP, EEMP dose-dependently inhibited the formation of calcium oxalate (CaOx) crystallization in the synthetic urine which was evident from the spectroscopic as well as in the microscopical studies. It was concluded that the antiurolithiatic activity of Mucuna pruriens was possibly mediated through inhibition CaOX crystals in the synthetic urine. But, further, in-vivo, preclinical studies are required to confirm its potential as Antiurolithiatic in terms of clinical use.

INTRODUCTION: Urolithiasis or Uroliths is the formation of stones in the kidney, bladder, ureter, urethra, or any part of the urinary tract. It occurs due to inadequate urinary drainage, presence of foreign bodies in the urinary tract, microbial infections, a diet rich with oxalates and calcium, vitamin deficiencies like vitamin A and metabolic disorders like hyperthyroidism, cystinuria, gout, *etc.* ¹ It affects about 10-12% of the world population, mostly in industrialized countries ².



It is the third most prevalent disorder in the urinary system with a recurrence rate of 50% ³. Urolithiasis occurs as a result of successive physiological events like supersaturation of urine, nucleation, growth, aggregation, and retention of calculi within the renal tubules ⁴. Renal calculi are composed of calcium oxalate, struvite, uric acid, and cysteine ⁵. But the majority of the renal stones are calculi of calcium oxalate crystals about 80% in the urinary tract ⁶.

The modern techniques like Extracorporeal Shock Wave Lithotripsy (ESWL), Ureteroscopy (URS), Percutaneous Nephrolithotomy (PNL) and open surgery are used if the renal calculi size is more than 5 mm but, these therapies showed significant side effects such as renal damage, renal tissue necrosis, hypertension, and damage to the surrounding organs ⁷. In addition to the modern techniques, conventional drugs like thiazide diuretics and calcium citrate were found to have limited efficacy and tolerability ⁸. On the other hand, herbal therapy is gaining importance among the public, especially for treating urolithiasis because of limited choice in allopathic medicines and have a recurrence rate of 50% at 10 years with this conventional therapy ⁹. However, herbal therapy was found to be efficient in depriving the recurrence rate of urolithiasis without side effects ¹⁰.

M. pruriens was folklorically used for inducing diuresis $^{11, 12}$ and also as a cleanser of kidney 13 . In the present study, an attempt was made to investigate the *in-vitro* antiurolithiatic potential of the whole plant of *M. pruriens* on inhibition of calcium oxalate crystallization.

MATERIALS AND METHODS:

Collection of Plant Material and Extraction: The whole plant of *M.pruriens* was collected from Neiyur dam, Kanyakumari district of Tamil Nadu, India. The authentication was made from the botanical survey of medicinal plants unit, Govt. of India, Palayamkottai. The obtained whole plant material of *M. pruriens* was shade dried, powdered and passed through 40 mesh sieve and stored in an airtight container.

The powdered plant material of the whole plant of M. pruriens was subjected for extraction by continuous hot percolation method successively by using methanol, ethyl acetate, and n-hexane as solvents with the same marc. The extracts were evaporated to dryness in a rotary flash evaporator at a temperature not exceeding 60 °C, then stored in an airtight container.

Preliminary Phytochemical Screening: The crude extracts were screened for the presence of phytochemicals like alkaloids, glycosides, carbohydrates, sterols, phenolic compounds and tannins, flavonoids, saponins, proteins, and amino acids by using the standard procedures ¹⁴.

Experimental Protocol: The effects of methanolic extract of *M. pruriens* (MEMP), ethanolic extract of *M. pruriens* (EEMP), and n-Hexane extract of *M. pruriens* (HEMP) on calcium oxalate crystallization were determined by measuring the

turbidity which was due to the addition of 0.01M sodium oxalate solution to the artificial urine. The turbidity was measured by using UV/visible spectrophotometer (Shimadzu) at 37 °C with pH 6.8 at 620 nm.

Preparation of Artificial Urine (AU): The artificial urine was prepared according to Burns and Finlayson method ¹⁵. It was prepared freshly for each time, and the pH has to be adjusted to 6.0.

Spectroscopic Studies: This method of analysis was just modified as specified in Goyal paveen Kumar *et al.* ¹⁶, and it has proceeded in the following way.

Without the Extracts of *M. pruriens:* To the 1ml of AU, add 0.5 ml of distilled water and blank reading was taken at 620 nm. Then to the above solution, 0.5ml of 0.01M sodium oxalate was added and incubated for 10 min. The absorbance was measured immediately for ten minutes. For each experiment, three replicates were taken.

With the Extracts of *M. pruriens:* The MEMP, EEMP, and HEMP were made to dissolve in water, filtered through the Whatman's filter paper and then different concentrations of 50µg m/ml, 100µg m/ml, 150µg m/ml, 200µg m/ml, and 250µg m/ml were prepared for each extract. A blank reading was taken with 1ml of AU and 0.5ml of plant extract solution, and then to the above, 0.5ml of 0.01M sodium oxalate solution was added and incubated for 10 min. The absorbance was observed to the above resulting solution at 620nm. For each experiment, three replicates were taken. The percentage of inhibition was calculated by using the following formula.

Percentage of Inhibition =
$$\{1-(At/Ao)\}$$

Where

At = Absorbance with the extract Ao = Absorbance without extract

Microscopic Studies: With the same experimental protocol as described in the above manner, the calcium oxalate crystals formed with and without the extract were observed by using a microscope which was equipped with a digital camera at 10X.

RESULTS: The preliminary phytochemical investigation of different extracts of *Mucuna*

carbohydrates, and coumarins.

pruriens revealed the presence of alkaloids, calcium glycosides, proteins, tannins, flavonoids, with EE

Effect of Extracts on Inhibition of Calcium Oxalate Crystals by Turbidity Method: The effect of the extracts on CaOX crystallization was determined by UV/visible spectroscopic method. The turbidity of artificial urine was measured with the presence of inhibitor (extract) and without inhibitor (without extract) at 620 nm. Then the percentage of inhibition was observed. All the extracts except HEMP showed inhibition of calcium oxalate crystallization in a dose-dependent manner **Table 1**. But, the methanolic extract of *Mucuna pruriens* showed significant inhibition on calcium oxalate crystallization when compared with EEMP and HEMP **Graph 1**.



INHIBITION COAX CRYSTALLIZATION

 TABLE 1: PERCENTAGE OF INHIBITION OF CALCIUM OXALATE CRYSTALS BY VARIOUS EXTRACTS OF

 MUCUNA PRURIE LINN.

S. no.	Extract of	Percentage of inhibition of Calcium Oxalate crystals [*]				
	Mucuna pruriens	50µgm/ml	100µgm/ml	150µgm/ml	200µgm/ml	250µgm/ml
1	MEMP	27.51%	32.61%	40.28%	52.9%	63.1%
2	EEMP	15.9%	22.3%	37.2%	41.09%	47.2%
3	HEMP	2.8%	9.66%	14.35%	1.2%	12.48%

*All values are triplicate

Microscopic Studies: The effect on CaOx crystallization without the addition of extract (control) is shown in **Fig. 1.** While **Fig. 2-6, 7-11, 12-16** showed the effect on CaOx crystallization with the addition of MEMP, EEMP, HEMP in different concentrations of 50µg m/ml, 100µg m/ml, 150µg m/ml, 200µg m/ml, and 250µg m/ml respectively.

Without Inhibitor (Without Mucuna pruriens Extract):





FIG. 1



FIG. 2

FIG. 7

FIG. 12



DISCUSSION: As earlier stated that kidney stone formation is a cascade process that results from successive physiochemical events of supersaturation, nucleation, growth, aggregation, and retention within the renal tubules. So, the

various research works for developing antiurolithiatic agent mainly focuses on preventing the above physiochemical events. The most common component of kidney stones was calcium oxalate, which is formed by supersaturation with

International Journal of Pharmaceutical Sciences and Research

later factors like nucleation, growth, and aggregation ¹⁷. Thus if the supersaturation or later physiochemical events can be prevented. urolithiasis can be made to avoid. However, several measures like increasing fluid intake and diuretics are commonly taken to reduce supersaturation, it is generally accepted that better strategies for preventing kidney stones need to be developed ¹⁸. As these *in-vitro* crystallization methods are widely used in urolithiasis research ¹⁹, we have studied the antiurolithiatic potential of *M. proteins* extracts using in *in-vitro* crystallization systems.

The results of the present study were found to be that MEMP and EEMP inhibited the crystallization of calcium oxalate dose-dependent manner; there were less and smaller particles with increasing concentrations of MEMP and EEMP as shown in various microphotographs, *i.e.*, Fig. 2-6 (MEMP), (EEMP) when compared Fig. 7-11 with microphotograph of calcium crystals without inhibitor (extract). Similar results were not found with HEMP even with the increase in concentration, shown in Fig. **12-16**. as Spectroscopically the results were found to be MEMP and EEMP showed a significant percentage of inhibition of calcium oxalate in in-vitro urolithiasis. It has been noted that the MEMP showed significant inhibition on calcium oxalate crystallization up to 63.1% with 250 µgm/ml. In addition to the above results, EEMP also showed the potential antiurolithiatic activity, but it is less when compare with MEMP. While HEMP did not show any significant results as like MEMP and EEMP even with the increase in concentration, which was tabulated in **Table. 1** and it was also evident from Graph 1. As a mean of evident of these spectroscopic results, the microscopic studies conformed the anti urolithiasis activity of MEMP and EEMP.

As the MEMP, EEMP reduces the number of crystals as well as the size of the crystals; it helps in reducing supersaturation, nucleation, and growth of crystals which are the critical events that eventually lead to the formation of uroliths. This property of MEMP and EEMP is therefore advantageous in preventing urolithiasis by avoiding urinary tract retention and thereby inducing urinary excretion. Furthermore, *M. pruriens* possesses the diuretic effect traditionally, which helps to reduce

the stone formation by inducing diuresis. The MEMP and EEMP may also contain substances that inhibit calcium oxalate crystal aggregation which help to reduce the crystal growth thereby reducing the urinary tract retention, as large crystals are less likely to pass spontaneously in the urinary tract ²⁰. By the above properties of MEMP and EEMP, it may cause the particles to be in dispersed form; thereby calcium oxalate crystals can be easily eliminated from the urinary tract which helps to prevent the kidney stone formation.

CONCLUSION: The methanol and ethyl acetate extracts of the whole plant of *Mucuna pruriens* have an inhibitory effect on calcium oxalate crystallization. These data suggest that the presence of antiurolithic effect is possibly due to CaOX crystal inhibition. But further preclinical and clinical studies were needed to evaluate and establish the use of this plant as antiurolithiatic activity.

ACKNOWLEDGEMENT: It is a pleasure to thank Dr. C. K. Ashok Kumar, M. Pharm, Ph. D, Principal, Sree Vidyanikethan College of pharmacy for providing the infrastructure and facilities.

I would like to extend my sincere thanks to Dr. D. Satheesh Kumar, M.pharm, Ph. D, Head of the department, Dept. of Pharmacology, Sree Vidyanikethan College of pharmacy for their valuable suggestions to complete this research work.

CONFLICT OF INTEREST: Nil

REFERENCES:

- 1. Mekap SK, Mishra S, Sahoo S and Panda PK: The antiurolithiatic activity of *Crataeva magna* Lour. Bark. Indian Journal of Natural Products and Resources 2011; 1(2): 28-33.
- 2. Moe OW: Kidney stones: pathophysiology and medical management. Lancet 2006; 367: 333-44.
- 3. Knoll T: Stone disease. European Urology Supplements 2007; 6: 717-22.
- Bouanani S, Henchiri C, Migianu-griffoni E, Aouf N and Lecouve M: Pharmacological and toxicological effects of *Paronychia argentea* in experimental calcium oxalate nephrolithiasis in rats. Journal of Ethnopharmacology 2010; 129: 38-45.
- 5. Worcester EM and Coe FL: Calcium kidney stones. N Engl J Med 2010; 363(10): 954-63.
- 6. Daudon M, Lacour B and Jungers P: High prevalence of uric acid calculi in diabetic stone formers. Nephrol Dial Transplant 2005; 20: 468-69.

- 7. Tombolini P, Ruoppolo M, Bellorofonte C, Zaatar C and Follini M: Lithotripsy in the treatment of urinary lithiasis. J Nephrol 2000; 13(3): S71-S82.
- 8. Hess B: Pathophysiology, diagnosis and conservative therapy in calcium kidney calculi. Therapeutische Umschau. Revue thérapeutique 2003; 60: 79-87.
- 9. Basavaraj DR, Biyani CS, Browning AJ and Cartledge JJ: The role of urinary kidney stone inhibitors and promoters in the pathogenesis of calcium-containing renal stones. EAU-EBU update series 2007; 5: 126-36.
- 10. Nadkarni KM: Indian Material Medica. Popular Prakashan, Mumbai, Edition 3, Vol. 1, 1976: 371-02.
- 11. Kasture S, Mohan M and Kasture V: *Mucuna pruriens* seeds in treatment of Parkinson's disease: a pharmacological review. Orient Pharm Exp Med 2013; 13: 165-74.
- 12. Duke JA, Bogenschutz-Godwin MJ, duCellier J and Duke PK: Handbook of Medicinal Herbs. CRC PRESS, New York, Edition 2, 2002: 228-29.
- Kirtikar KR and Basu BD: Indian Medicinal Plants. Indian press, Allahabad, Edition 2, 1918: 437-38.

- 14. Kokate CK: Pharmacognosy. Nirali Prakashan, Pune, Edition 17, 2001: 106-7.
- 15. Burns JR and Finlayson B: A proposal for standard reference of artificial urine in *in-vitro* urolithiasis experiments. J Urol 1980; 18: 167-9.
- 16. Kumar GP, Arun M and Kumar R: Evaluation of *Tinospora cordifolia* for antiurolithiatic potential. Journal of Pharmaceutical and Biomedical Sci 2011; 9(14): 1-5.
- Khan SR: Structure and development of calcific urinary stones, in: Calcification in Biological Systems. CRC Press, Florida 1992: 345-63.
- Atmani F and Khan SR: Effects of an extract from *Herniaria hirsuta* on calcium oxalate crystallization in vitro. British J Urology International 2000; 85: 621-5.
- 19. Saha S and Verma RJ: Inhibition of calcium oxalate crystallization *in-vitro* by an extract of *Bergenia ciliate*. Arab Journal of Urology 2013; 11: 187-92.
- Coll DM, Varanelli MJ and Smith RC: Relationship of spontaneous passage of ureteral calculi to stone size and location as revealed by unenhanced helical CT. Am J Roentgenol 2002; 178: 101-03.

How to cite this article:

Vamsi S, Raviteja M and Kumar GS: *In-vitro* antiurolithiatic potential of various extracts of *Mucuna pruriens*. Int J Pharm Sci & Res 2014; 5(9): 3897-02. doi: 10.13040/IJPSR.0975-8232.5(9).3897-02.

All © 2013 are reserved by International Journal of Pharmaceutical Sciences and Research. This Journal licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License.

This article can be downloaded to ANDROID OS based mobile. Scan QR Code using Code/Bar Scanner from your mobile. (Scanners are available on Google Playstore)